Wikipedia -WSS

Wikipedia

author：entertainment 2025-09-27 13:11:05 - browse：9

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

Roche said Monday it was buying Telavant Holdings for $7.1 billion upfront, picking up a promising experimental therapy for inflammatory bowel diseases.

Telavant is owned by Roivant Sciences, with Pfizer holding a minority stake. The deal will allow Roche to develop the therapy, called RVT-3101, and, pending approval, sell it in the United States and Japan. Pfizer holds the commercial rights in other parts of the world.

The “Roi” in Roivant stands for “return on investment” and with this deal, the biotech, founded by Republican presidential candidate Vivek Ramaswamy but now run by CEO Matt Gline, certainly delivered. Last December, it essentially acquired RVT-3101 from Pfizer for $45 million and a commitment to invest in the drug’s development. Less than a year later, Roivant flipped the drug to Roche for at least $7.1 billion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Grad students accuse University of California of wage theft

focus

WSS

Grad students accuse University of California of wage theft

The unintended consequences of overturning Roe v. Wade

David Liu startup to focus on CRISPR delivery

People with substance use disorder deserve online privacy

Bernie brings in new pharma CEOs to talk drug prices

A single Democrat is willing to weaken Medicare negotiation power

focus

Wikipedia

leisure time

Wildfire smoke exposes gaps in outdoor worker protections

Texas Medical Board asked to define abortion emergency exception

Drug repurposing or repositioning? The language matters

Unique patient identifier: Experts argue the benefits, pitfalls

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Fed up with FDA, ALS advocates consider a take

Medical leaders decry Supreme Court decision on affirmative action

What’s missing from the debate over nursing home staff minimums

In age of alternative facts, a scholarly course on calling out crap

Why Novartis is going to walk from its acquisition of MorphoSys

hotspot

Senate bill would ban some hospital facility fees

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Surgery pushed Ben Carson to fame

Covid’s new normal has set in amid another rise in cases

AstraZeneca stays mum on Medicare drug pricing negotiations

340B reform proposal comes out of Senate working group

hotspot

focus

hotspot

knowledge